Grantees in the News: Randall Bateman, MD, and Alzheimer’s Therapy Trials BACK

A June 7 story in The New York Times Magazine featured Randall Bateman, MD, and his work in the Dominantly Inherited Alzheimer Network (DIAN). DIAN is an international study of volunteers who have a rare form of inherited Alzheimer’s disease (AD) to analyze the progression of AD in the brain in the years before AD is typically diagnosed. Based on the changes they have observed in these participants’ brains, Dr. Bateman and DIAN researchers have determined that the best time to begin treating AD is likely to be fifteen years before symptoms are usually identified. Dr. Bateman is beginning trials with DIAN participants who possess an AD-causing gene in this window before the onset of symptoms, in hopes of identifying a preventative therapy for AD.

Dr. Bateman is the recipient of a 2007 Paul B. Beeson Career Development Award in Aging Research. He is also the winner of a 2012 MetLife Foundation Promising Investigator Award for Medical Research in Alzheimer’s Disease.

BACK TO TOP